EP1651270B1 - Medikamente zur inhalation mit betamimetika und einem anticholinergikum - Google Patents

Medikamente zur inhalation mit betamimetika und einem anticholinergikum Download PDF

Info

Publication number
EP1651270B1
EP1651270B1 EP04741130A EP04741130A EP1651270B1 EP 1651270 B1 EP1651270 B1 EP 1651270B1 EP 04741130 A EP04741130 A EP 04741130A EP 04741130 A EP04741130 A EP 04741130A EP 1651270 B1 EP1651270 B1 EP 1651270B1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
ethanol
acid
methyl
benzoxazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP04741130A
Other languages
English (en)
French (fr)
Other versions
EP1651270A1 (de
Inventor
Christopher John Montague Meade
Michel Pairet
Michael P. Pieper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1651270(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim International GmbH
Priority to SI200430315T priority Critical patent/SI1651270T1/sl
Priority to EP06122278A priority patent/EP1803469A3/de
Priority to PL04741130T priority patent/PL1651270T3/pl
Priority to EP04741130A priority patent/EP1651270B1/de
Publication of EP1651270A1 publication Critical patent/EP1651270A1/de
Application granted granted Critical
Publication of EP1651270B1 publication Critical patent/EP1651270B1/de
Priority to CY20071100456T priority patent/CY1106430T1/el
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel pharmaceutical compositions based on beta 2 agonists and salts of an anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints.
  • the present invention relates to novel pharmaceutical compositions based on beta 2 agonists and salts of an anticholinergic 1 , processes for preparing them and their use in the treatment of respiratory complaints.
  • anticholinergic agents used are the salts of formula 1 wherein
  • salts of formula 1 are used wherein
  • an unexpectedly beneficial therapeutic effect can be observed in the treatment of inflammatory and/or obstructive diseases of the respiratory tract if the anticholinergic of f ormula 1 is used with one or more betamimetics 2.
  • the active substances may be combined in a single preparation or contained in two separate formulations.
  • Pharmaceutical compositions which contain the active substances 1 and 2 in a single preparation are preferred according to the invention.
  • beta 2 agonists 2 in the combinations according to the invention are selected from the group consisting of albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmeterol, salmefamol, soterenot, sulphonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3-(4- ⁇ 6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-
  • beta 2 agonists 2 are selected from the group consisting of bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, pirbuterol, procaterol, reproterol, salmeterol, sulphonterol, terbutaline, tolubuterol, 3-(4- ⁇ 6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy ⁇ -butyl)-benzenesulfoneamide, 5-[2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H -quinolin-2-one , 4-hydroxy-7-[2- ⁇ [2- ⁇ [3-(2-phenylethoxy)propyl]sulphonyl ⁇ ethyl]-amino ⁇ eth
  • the betamimetics 2 used as within the compositions according to the invention are selected from among fenoterol, formoterol, salmeterol, 3-(4- ⁇ 6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy ⁇ -butyl)-benzenesulfoneamide, 5-[2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H -quinolin-2-one , 1-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propy
  • the compounds formoterol and salmeterol are particularly preferred, optionally in the form of the racemates, the enantiomers, the diastereomers and optionally the pharmacologically acceptable acid addition salts thereof, and the hydrates thereof.
  • Examples of pharmacologically acceptable acid addition salts of the betamimetics 2 according to the invention are the pharmaceutically acceptable salts which are selected from among the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, 1-hydroxy-2-naphthalenecarboxylic acid, 4-phenylcinnamic acid, 5-(2.4-difluorophenyl)salicylic acid or maleic acid. If desired, mixtures of the abovementioned acids may also be used to prepare the salts 2.
  • the salts of the betamimetics 2 selected from among the hydrochloride, hydrobromide, sulphate, phosphate, fumarate, methanesulphonate, 4-phenylcinnamate, 5-(2.4-difluorophenyl)salicylate, maleate and xinafoate are preferred.
  • salts of 2 in the case of salmeterol selected from among the hydrochloride, sulphate, 4-phenylcinnamate, 5-(2.4-difluorophenyl)salicylate and xinafoate, of which the 4-phenylcinnamate, 5-(2.4-difluorophenyl)salicylate and especially xinafoate are particularly important.
  • salts of 2 in the case of formoterol selected from the hydrochloride, sulphate and fumarate, of which the hydrochloride and fumarate are particularly preferred. Of exceptional importance according to the invention is formoterol fumarate.
  • betamimetics 2 Salts of salmeterol, formoterol, 3-(4- ⁇ 6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino]-hexyloxy ⁇ -butyl)-benzenesulfoneamide, and 5-[2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H -quinolin-2-one , are preferably used as the betamimetics 2 according to the invention. Of particular importance according to the invention are salmeterol and formoterol salts. Any reference to the term betamimetics 2 also includes a reference to the relevant enantiomers or mixtures thereof.
  • the compounds 2 may be present in the form of their racemates, enantiomers or mixtures thereof.
  • the separation of the enantiomers from the racemates may be carried out using methods known in the art (e.g. by chromatography on chiral phases, etc.) If the compounds 2 are used in the form of their enantiomers, it is particularly preferable to use the enantiomers in the R configuration at the C-OH group.
  • any reference to the most preferred compounds 2 according to the invention also includes the relevant enantiomeric salts of R -salmeterol, S-salmeterol, R,R- formoterol, S,S -formoterol, R,S -formoterol, S,R- formoterol and the mixtures thereof, while the enantiomeric salts of R -salmeterol and R,R- formoterol are of particular importance.
  • the compounds 2 may also be present according to the invention in the form of the hydrates or solvates thereof.
  • betamimetics which are not in the form of salts
  • this is indicated by a reference to compounds 2' .
  • the preferred betamimetics 2' according to the invention which are not in salt form include the free base of formoterol, salmeterol whereas the particularly preferred compounds 2 according to the invention are salmeterol xinafoate or formoterol fumarate.
  • betamimetics 2 may possibly also be referred to as sympathomimetics or beta-2-agonists ( ⁇ 2 -agonists). All these terms are to be regarded as interchangeable for the purposes of the present invention.
  • the present invention relates to the abovementioned pharmaceutical compositions which contain, in addition to therapeutically effective quantities of 1 and 2 , a pharmaceutically acceptable carrier.
  • the present invention relates to the abovementioned pharmaceutical compositions which do not contain any pharmaceutically acceptable carrier in addition to therapeutically effective quantities of 1 and 2.
  • the present invention also relates to the use of therapeutically effective quantities of the salts 1 for preparing a pharmaceutical composition containing betamimetics 2 for treating inflammatory or obstructive diseases of the respiratory tract.
  • the present invention relates to the abovementioned use for preparing a pharmaceutical composition for treating asthma or COPD.
  • the compounds 1 and 2 may be administered simultaneously or successively, while it is preferable according to the invention to administer compounds 1 und 2 simultaneously.
  • the present invention further relates to the use of therapeutically effect amounts of salts 1 and betamimetics 2 for treating inflammatory or obstructive respiratory complaints, particularly asthma or COPD.
  • the proportions in which the active substances 1 and 2 may be used in the active substance combinations according to the invention are variable. Active substances 1 and 2 may possibly be present in the form of their solvates or hydrates. Depending on the choice of the compounds 1 and 2 , the weight ratios which may be used within the scope of the present invention vary on the basis of the different molecular weights of the various salt forms.
  • the pharmaceutical combinations according to the invention may contain 1 and 2' generally in ratios by weight ranging from 1:5 to 500:1, preferably from 1:10 to 400:1.
  • weight ratios specified below were based on the bromide of compound 1 and the free bases 2 ' of the betamimetics salmeterol and formoterol which are particularly preferred according to the invention.
  • the pharmaceutical combinations according to the invention may contain 1 and 2' in the case of formoterol, for example, in ratios by weight ranging from 1:10 to 300:1, preferably from 1:5 to 200:1, preferably 1:3 to 150:1, more preferably from 1:2 to 100:1.
  • preferred combinations of 1 and 2 according to the invention may contain the bromide 1 and formoterol 2 ' in the following weight ratios: 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1,40:1,41:1,42:1, 43:1, 44:1, 45:1, 46:1, 47:1, 48:1, 49:1, 50:1, 51:1, 52:1, 53:1, 54:1, 55:1, 56:1, 57:1, 58:1, 59:1, 60:1, 61:1, 62:1, 63:1, 64:1, 65:1,
  • compositions according to the invention containing the combinations of 1 and 2 are normally administered so that the bromide 1 and formoterol 2' are present together in doses of 5 to 5000 ⁇ g, preferably from 10 to 2000 ⁇ g, more preferably from 15 to 1000 ⁇ g, better still from 20 to 800 ⁇ g per single dose.
  • combinations of 1 and 2 according to the invention contain a quantity of the bromide of formula 1 and formoterol 2' such that the total dosage per single dose is about 10 ⁇ g, 15 ⁇ g, 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 35 ⁇ g, 45 ⁇ g, 50 ⁇ g, 55 ⁇ g, 60 ⁇ g, 65 ⁇ g, 70 ⁇ g, 75 ⁇ g, 80 ⁇ g, 85 ⁇ g, 90 ⁇ g, 95 ⁇ g, 100 ⁇ g, 105 ⁇ g, 110 ⁇ g, 115 ⁇ g, 120 ⁇ g, 125 ⁇ g, 130 ⁇ g, 135 ⁇ g, 140 ⁇ g, 145 ⁇ g, 150 ⁇ g, 155 ⁇ g, 160 ⁇ g, 165 ⁇ g, 170 ⁇ g, 175 ⁇ g, 180 ⁇ g, 185 ⁇ g, 190 ⁇ g, 195 ⁇ g, 200 ⁇ g, 205 ⁇ g, 210 ⁇ g, 215 ⁇ g, 220 ⁇ g, 225 ⁇ g, 230 ⁇ g, 235 ⁇ g, 240 ⁇ g, 245 ⁇ g, 250 ⁇ g,
  • the pharmaceutical compositions according to the invention may contain for instance the following quantities for each single dose: 20 ⁇ g of 1 and 2.9 ⁇ g of 2 , 20 ⁇ g of 1 and 5.7 ⁇ g of 2 , 20 ⁇ g of 1 and 11.5 ⁇ g of 2 , 20 ⁇ g of 1 and 17.2 ⁇ g of 2 , 20 ⁇ g of 1 and 22.9 ⁇ g of 2 , 20 ⁇ g of 1 and 28.5 ⁇ g of 2 , 40 ⁇ g of 1 and 2.9 ⁇ g of 2 , 40 ⁇ g of 1 and 5.7 ⁇ g of 2 , 40 ⁇ g of 1 and 11.5 ⁇ g of 2 , 40 ⁇ g of 1 and 17.2 ⁇ g of 2 , 40 ⁇ g of 1 and 22.9 ⁇ g of 2 , 40 ⁇ g of 1 and 28.5 ⁇ g of 2 , 60 ⁇ g of 1 and 2.9 ⁇ g of 2
  • the active substance combinations according to the invention may contain the bromide 1 and 2' , in the case of salmeterol, in ratios by weight in the range from about 1:30 to 400:1, preferably 1:25 to 200:1, preferably 1:20 to 100:1, more preferably from 1:15 to 50:1.
  • preferred combinations of 1 and 2 according to the invention may contain the bromide of formula 1 and salmeterol 2' in the following ratios by weight: 1:15, 1:14, 1:13,1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1.
  • compositions according to the invention containing the combinations of 1 and 2 are usually administered so that the bromide of formula 1 and salmeterol 2' are present together in dosages of 5 to 5000 ⁇ g, preferably from 10 to 2000 ⁇ g, more preferably from 15 to 1000 ⁇ g, even more preferably from 20 to 800 ⁇ g per single dose.
  • combinations of 1 and 2 according to the invention contain an amount of the bromide of formula 1 and salmeterol 2' such that the total dosage per single dose is about 15 ⁇ g, 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 35 ⁇ g, 45 ⁇ g, 50 ⁇ g, 55 ⁇ g, 60 ⁇ g, 65 ⁇ g, 70 ⁇ g, 75 ⁇ g, 80 ⁇ g, 85 ⁇ g, 90 ⁇ g, 95 ⁇ g, 100 ⁇ g, 105 ⁇ g, 110 ⁇ g, 115 ⁇ g, 120 ⁇ g, 125 ⁇ g, 130 ⁇ g, 135 ⁇ g, 140 ⁇ g, 145 ⁇ g, 150 ⁇ g, 155 ⁇ g, 160 ⁇ g, 165 ⁇ g, 170 ⁇ g, 175 ⁇ g, 180 ⁇ g, 185 ⁇ g, 190 ⁇ g, 195 ⁇ g, 200 ⁇ g, 205 ⁇ g, 210 ⁇ g, 215 ⁇ g, 220 ⁇ g, 225 ⁇ g, 230 ⁇ g, 235 ⁇ g, 240 ⁇ g, 245 ⁇ g, 250 ⁇ g, 255 ⁇ g,
  • the pharmaceutical compositions according to the invention may contain for instance the following quantities for each single dose: 20 ⁇ g of 1 and 18.2 ⁇ g of 2 , 20 ⁇ g of 1 and 36.3 ⁇ g of 2 , 20 ⁇ g of 1 and 72.6 ⁇ g of 2 , 20 ⁇ g of 1 and 108.9 ⁇ g of 2 , 20 ⁇ g of 1 and 145.2 ⁇ g of 2 , 20 ⁇ g of 1 and 290.4 ⁇ g of 2 , 40 ⁇ g of 1 and 18.2 ⁇ g of 2 , 40 ⁇ g of 1 and 36.3 ⁇ g of 2 , 40 ⁇ g of 1 and 72.6 ⁇ g of 2 , 40 ⁇ g of 1 and 108.9 ⁇ g of 2 , 40 ⁇ g of 1 and 145.2 ⁇ g of 2 , 40 ⁇ g of 1 and 290.4 ⁇ g of 2 , 60 ⁇ g of
  • the aforementioned examples of possible doses applicable for the combinations according to the invention are to be understood as referring to doses per single application. However, these examples are not be understood as excluding the possibility of administering the combinations according to the invention multiple times. Depending on the medical need patients may receive also multiple inhalative applications. As an example patients may receive the combinations according to the invention for instance two or three times (e.g. two or three puffs with a powder inhaler, an MDI etc) in the morning of each treatment day. As the aforementioned dose examples are only to be understood as dose examples per single application (i.e. per puff) multiple application of the combinations according to the invention leads to multiple doses of the aforementioned examples.
  • the application of the combositions according to the invention can be for instance once a day, or depending on the duration of action of the anticholinergic agent twice a day, or once every 2 or 3 days.
  • the aforementioned dose examples are to be understood as examples of metered doses only. In other terms, the aforementioned dose examples are not to be understood as the effective doses of the combinations according to the invention that do in fact reach the lung. It is clear for the person of ordinary skill in the art that the delivered dose to the lung is generally lower than the metered dose of the administered active ingredients.
  • the active substance combinations of 1 and 2 according to the invention are preferably administered by inhalation.
  • ingredients 1 and 2 have to be made available in forms suitable for inhalation.
  • Inhalable preparations according to the invention include inhalable powders, propellant-containing metered dose aerosols or propellant-free inhalable solutions.
  • Inhalable powders according to the invention containing the combination of active substances 1 and 2 may consist of the active substances on their own or of a mixture of the active substances with physiologically acceptable excipients.
  • the term carrier may optionally be used instead of the term excipient.
  • propellant-free inhalable solutions also includes concentrates or sterile inhalable solutions ready for use.
  • the preparations according to the invention may contain the combination of active substances 1 and 2 either together in one formulation or in two separate formulations. These formulations which may be used within the scope of the present invention are described in more detail in the next part of the specification.
  • the inhalable powders according to the invention may contain 1 and 2 either on their own or in admixture with suitable physiologically acceptable excipients. If the active substances 1 and 2 are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose, trehalose), oligo- and polysaccharides (e.g. dextran), polyalcohols (e.g. sorbitol, mannitol, xylitol), cyclodextrines (e.g.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, saccharose, maltose, trehalose
  • oligo- and polysaccharides e.g. dextran
  • ⁇ -cyclodextrine ⁇ -cyclodextrine, ⁇ -cyclodextrine, ⁇ -cyclodextrine, methyl- ⁇ -cyclodextrine, hydroxypropyl- ⁇ -cyclodextrine
  • salts e.g. sodium chloride, calcium carbonate
  • mono- or disaccharides are used, while the use of lactose, trehalose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates.
  • the excipients have a maximum average particle size of up to 250 ⁇ m, preferably between 10 and 150 ⁇ m, most preferably between 15 and 80 ⁇ m. It may sometimes seem appropriate to add finer excipient fractions with an average particle size of 1 to 9 ⁇ m to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to prepare the inhalable powders according to the invention, micronised active substance 1 and 2 , preferably with an average particle size of 0.5 to 10 ⁇ m, more preferably from 1 to 6 ⁇ m, is added to the excipient mixture.
  • inhalable powders according to the invention may be prepared and administered either in the form of a single powder mixture which contains both 1 and 2 or in the form of separate inhalable powders which contain only 1 or 2.
  • the inhalable powders according to the invention may be administered using inhalers known from the prior art.
  • Inhalable powders according to the invention which contain one or more physiologically acceptable excipients in addition to 1 and 2 may be administered, for example, by means of inhalers which deliver a single dose from a supply using a measuring chamber as described in US 4570630A, or by other means as described in DE 36 25 685 A.
  • the inhalable powders according to the invention which contain 1 and 2 optionally in conjunction with a physiologically acceptable excipient may be administered, for example, using the inhaler known by the name Turbuhaler ® or using inhalers as disclosed for example in EP 237507 A.
  • the inhalable powders according to the invention which contain physiologically acceptable excipient in addition to 1 and 2 are packed into capsules (to produce so-called inhalettes) which are used in inhalers as described, for example, in WO 94/28958.
  • FIG. 1 A particularly preferred inhaler for using the pharmaceutical combination according to the invention in inhalettes is shown in Figure 1.
  • This inhaler for inhaling powdered pharmaceutical compositions from capsules is characterised by a housing 1 containing two windows 2, a deck 3 in which there are air inlet ports and which is provided with a screen 5 secured via a screen housing 4, an inhalation chamber 6 connected to the deck 3 on which there is a push button 9 provided with two sharpened pins 7 and movable counter to a spring 8, and a mouthpiece 12 which is connected to the housing 1, the deck 3 and a cover 11 via a spindle 10 to enable it to be flipped open or shut, as well as airholes 13 for adjusting the flow resistance.
  • a housing 1 containing two windows 2, a deck 3 in which there are air inlet ports and which is provided with a screen 5 secured via a screen housing 4, an inhalation chamber 6 connected to the deck 3 on which there is a push button 9 provided with two sharpened pins 7 and movable counter to a spring
  • the quantities packed into each capsule should be 1 to 30mg per capsule.
  • These capsules contain, according to the invention, either together or separately, the doses of 1 and 2 or 2' mentioned hereinbefore for each single dose.
  • Inhalation aerosols containing propellant gas according to the invention may contain substances 1 and 2 dissolved in the propellant gas or in dispersed form. 1 and 2 may be present in separate formulations or in a single preparation, in which 1 and 2 are either both dissolved, both dispersed or only one component is dissolved and the other is dispersed.
  • the propellant gases which may be used to prepare the inhalation aerosols according to the invention are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • propellant gases mentioned above may be used on their own or in mixtures thereof.
  • Particularly preferred propellant gases are halogenated alkane derivatives selected from TG11, TG12, TG134a (1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof, of which the propellant gases TG134a, TG227 and mixtures thereof are preferred.
  • the propellant-driven inhalation aerosols according to the invention may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.
  • the inhalation aerosols containing propellant gas according to the invention may contain up to 5 wt.-% of active substance 1 and/or 2 .
  • Aerosols according to the invention contain, for example, 0.002 to 5 wt.-%, 0.01 to 3 wt.-%, 0.015 to 2 wt.-%, 0.1 to 2 wt.-%, 0.5 to 2 wt.-% or 0.5 to 1 wt.-% of active substance 1 and/or 2.
  • the particles of active substance preferably have an average particle size of up to 10 ⁇ m, preferably from 0.1 to 6 ⁇ m, more preferably from 1 to 5 ⁇ m.
  • the present invention relates to pharmaceutical compositions in the form of propellant-driven aerosols as hereinbefore described combined with one or more inhalers suitable for administering these aerosols.
  • the present invention relates to inhalers which are characterised in that they contain the propellant gas-containing aerosols described above according to the invention.
  • the present invention also relates to cartridges fitted with a suitable valve which can be used in a suitable inhaler and which contain one of the above-mentioned propellant gas-containing inhalation aerosols according to the invention. Suitable cartridges and methods of filling these cartridges with the inhalable aerosols containing propellant gas according to the invention are known from the prior art.
  • Propellant-free inhalable solutions and suspensions according to the invention contain, for example, aqueous or alcoholic, preferably ethanolic solvents, optionally ethanolic solvents mixed with aqueous solvents. If aqueous/ethanolic solvent mixtures are used the relative proportion of ethanol compared with water is not limited but preferably the maximum is up to 70 percent by volume, more particularly up to 60 percent by volume of ethanol. The remainder of the volume is made up of water.
  • the solutions or suspensions containing 1 and 2 are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids.
  • Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid.
  • Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc.
  • Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred.
  • mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example.
  • the addition of editic acid (EDTA) or one of the known salts thereof, sodium editate, as stabiliser or complexing agent is unnecessary in the present formulation.
  • Other embodiments may contain this compound or these compounds.
  • the content based on sodium editate is less than 100mg/100ml, preferably less than 50mg/100 ml, more preferably less than 20mg/100 ml.
  • inhalable solutions in which the content of sodium editate is from 0 to 10mg/100ml are preferred.
  • Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions according to the invention.
  • Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the pharmacologically suitable solvent in order to improve the qualitative properties of the active substance formulation:
  • these substances Preferably, these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect.
  • the excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art.
  • the additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
  • the preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
  • Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art.
  • the preservatives mentioned above are preferably present in concentrations of up to 50mg/100ml, more preferably between 5 and 20mg/100ml.
  • Preferred formulations contain, in addition to the solvent water and the combination of active substances 1 and 2 , only benzalkonium chloride and sodium editate. In another preferred embodiment, no sodium editate is present.
  • the propellant-free inhalable solutions according to the invention are administered in particular using inhalers of the kind which are capable of nebulising a small amount of a liquid formulation in the therapeutic dose within a few seconds to produce an aerosol suitable for therapeutic inhalation.
  • preferred inhalers are those in which a quantity of less than 100 ⁇ L, preferably less than 50 ⁇ L, more preferably between 20 and 30 ⁇ L of active substance solution can be nebulised in preferably one spray action to form an aerosol with an average particle size of less than 20 ⁇ m, preferably less than 10 ⁇ m, in such a way that the inhalable part of the aerosol corresponds to the therapeutically effective quantity.
  • nebulisers devices described therein are known by the name Respimat®.
  • This nebuliser can advantageously be used to produce the inhalable aerosols according to the invention containing the combination of active substances 1 and 2 . Because of its cylindrical shape and handy size of less than 9 to 15 cm long and 2 to 4 cm wide, this device can be carried at all times by the patient.
  • the nebuliser sprays a defined volume of pharmaceutical formulation using high pressures through small nozzles so as to produce inhalable aerosols.
  • the preferred atomiser essentially consists of an upper housing part, a pump housing, a nozzle, a locking mechanism, a spring housing, a spring and a storage container, characterised by
  • the hollow plunger with valve body corresponds to a device disclosed in WO 97/12687. It projects partially into the cylinder of the pump housing and is axially movable within the cylinder. Reference is made in particular to Figures 1 to 4, especially Figure 3, and the relevant parts of the description.
  • the hollow plunger with valve body exerts a pressure of 5 to 60 Mpa (about 50 to 600 bar), preferably 10 to 60 Mpa (about 100 to 600 bar) on the fluid, the measured amount of active substance solution, at its high pressure end at the moment when the spring is actuated. Volumes of 10 to 50 microlitres are preferred, while volumes of 10 to 20 microlitres are particularly preferred and a volume of 15 microlitres per spray is most particularly preferred.
  • the valve body is preferably mounted at the end of the hollow plunger facing the valve body.
  • the nozzle in the nozzle body is preferably microstructured, i.e. produced by microtechnology.
  • Microstructured nozzle bodies are disclosed for example in WO 94/07607; reference is hereby made to the contents of this specification, particularly Figure 1 therein and the associated description.
  • the nozzle body consists for example of two sheets of glass and/or silicon firmly joined together, at least one of which has one or more microstructured channels which connect the nozzle inlet end to the nozzle outlet end.
  • At the nozzle outlet end there is at least one round or non-round opening 2 to 10 microns deep and 5 to 15 microns wide, the depth preferably being 4.5 to 6.5 microns while the length is preferably 7 to 9 microns.
  • the directions of spraying of the nozzles in the nozzle body may extend parallel to one another or may be inclined relative to one another in the direction of the nozzle opening.
  • the directions of spraying may be at an angle of 20 to 160° to one another, preferably 60 to 150°, most preferably 80 to 100°.
  • the nozzle openings are preferably arranged at a spacing of 10 to 200 microns, more preferably at a spacing of 10 to 100 microns, most preferably 30 to 70 microns. Spacings of 50 microns are most preferred.
  • the directions of spraying will therefore meet in the vicinity of the nozzle openings.
  • the liquid pharmaceutical preparation strikes the nozzle body with an entry pressure of up to 600 bar, preferably 200 to 300 bar, and is atomised into an inhalable aerosol through the nozzle openings.
  • the preferred particle or droplet sizes of the aerosol are up to 20 microns, preferably 3 to 10 microns.
  • the locking mechanism contains a spring, preferably a cylindrical helical compression spring, as a store for the mechanical energy.
  • the spring acts on the power takeoff flange as an actuating member the movement of which is determined by the position of a locking member.
  • the travel of the power takeoff flange is precisely limited by an upper and lower stop.
  • the spring is preferably biased, via a power step-up gear, e.g. a helical thrust gear, by an external torque which is produced when the upper housing part is rotated counter to the spring housing in the lower housing part.
  • the upper housing part and the power takeoff flange have a single or multiple V-shaped gear.
  • the locking member with engaging locking surfaces is arranged in a ring around the power takeoff flange. It consists, for example, of a ring of plastic or metal which is inherently radially elastically deformable.
  • the ring is arranged in a plane at right angles to the atomiser axis. After the biasing of the spring, the locking surfaces of the locking member move into the path of the power takeoff flange and prevent the spring from relaxing.
  • the locking member is actuated by means of a button.
  • the actuating button is connected or coupled to the locking member. In order to actuate the locking mechanism, the actuating button is moved parallel to the annular plane, preferably into the atomiser; this causes the deformable ring to deform in the annular plane. Details of the construction of the locking mechanism are given in WO 97/20590.
  • the lower housing part is pushed axially over the spring housing and covers the mounting, the drive of the spindle and the storage container for the fluid.
  • the upper housing part is rotated relative to the lower housing part, the lower housing part taking the spring housing with it.
  • the spring is thereby compressed and biased by means of the helical thrust gear and the locking mechanism engages automatically.
  • the angle of rotation is preferably a whole-number fraction of 360 degrees, e.g. 180 degrees.
  • the power takeoff part in the upper housing part is moved along by a given distance, the hollow plunger is withdrawn inside the cylinder in the pump housing, as a result of which some of the fluid is sucked out of the storage container and into the high pressure chamber in front of the nozzle.
  • a number of exchangeable storage containers which contain the fluid to be atomised may be pushed into the atomiser one after another and used in succession.
  • the storage container contains the aqueous aerosol preparation according to the invention.
  • the atomising process is initiated by pressing gently on the actuating button.
  • the locking mechanism opens up the path for the power takeoff member.
  • the biased spring pushes the plunger into the cylinder of the pump housing.
  • the fluid leaves the nozzle of the atomiser in atomised form.
  • the components of the atomiser are made of a material which is suitable for its purpose.
  • the housing of the atomiser and, if its operation permits, other parts as well, are preferably made of plastics, e.g. by injection moulding. For medicinal purposes, physiologically safe materials are used.
  • Figures 6a/b of WO 97/12687 show the nebuliser (Respimat®) which can advantageously be used for inhaling the aqueous aerosol preparations according to the invention.
  • Figure 6a of WO 97/12687 shows a longitudinal section through the atomiser with the spring biased while Figure 6b of WO 97/12687 shows a longitudinal section through the atomiser with the spring relaxed.
  • the upper housing part (51) contains the pump housing (52) on the end of which is mounted the holder (53) for the atomiser nozzle.
  • the nozzle body (54) In the holder is the nozzle body (54) and a filter (55).
  • the hollow plunger (57) fixed in the power takeoff flange (56) of the locking mechanism projects partially into the cylinder of the pump housing.
  • the hollow plunger carries the valve body (58).
  • the hollow plunger is sealed off by means of the seal (59).
  • Inside the upper housing part is the stop (60) on which the power takeoff flange abuts when the spring is relaxed.
  • the stop (61) On the power takeoff flange is the stop (61) on which the power takeoff flange abuts when the spring is biased.
  • the locking member (62) moves between the stop (61) and a support (63) in the upper housing part.
  • the actuating button (64) is connected to the locking member.
  • the upper housing part ends in the mouthpiece (65) and is sealed off by means of the protective cover (66) which can be placed thereon.
  • the spring housing (67) with compression spring (68) is rotatably mounted on the upper housing part by means of the snap-in lugs (69) and rotary bearing.
  • the lower housing part (70) is pushed over the spring housing.
  • the exchangeable storage container (71) for the fluid (72) which is to be atomised.
  • the storage container is sealed off by the stopper (73) through which the hollow plunger projects into the storage container and is immersed at its end in the fluid (supply of active substance solution).
  • the spindle (74) for the mechanical counter is mounted in the covering of the spring housing. At the end of the spindle facing the upper housing part is the drive pinion (75). The slider (76) sits on the spindle.
  • the nebuliser described above is suitable for nebulising the aerosol preparations according to the invention to produce an aerosol suitable for inhalation.
  • the quantity delivered should correspond to a defined quantity with a tolerance of not more than 25%, preferably 20% of this amount in at least 97%, preferably at least 98% of all operations of the inhaler (spray actuations).
  • the quantity delivered should correspond to a defined quantity with a tolerance of not more than 25%, preferably 20% of this amount in at least 97%, preferably at least 98% of all operations of the inhaler (spray actuations).
  • Preferably, between 5 and 30 mg of formulation, most preferably between 5 and 20 mg of formulation are delivered as a defined mass on each actuation.
  • formulation according to the invention may also be nebulised by means of inhalers other than those described above, e.g. jet stream inhalers or other stationary nebulisers.
  • the invention relates to pharmaceutical formulations in the form of propellant-free inhalable solutions or suspensions as described above combined with a device suitable for administering these formulations, preferably in conjunction with the Respimat®.
  • the invention relates to propellant-free inhalable solutions or suspensions characterised by the combination of active substances 1 and 2 according to the invention in conjunction with the device known by the name Respimat®.
  • the present invention relates to the above-mentioned devices for inhalation, preferably the Respimat®, characterised in that they contain the propellant-free inhalable solutions or suspensions according to the invention as described hereinbefore.
  • inhalable solutions which contain the active substances 1 and 2 in a single preparation are preferred.
  • single preparation also includes preparations which contain the two ingredients 1 and 2 in two-chamber cartridges, as disclosed for example in WO 00/23037. Reference is hereby made to this publication in its entirety.
  • the propellant-free inhalable solutions or suspensions according to the invention may take the form of concentrates or sterile inhalable solutions or suspensions ready for use, as well as the above-mentioned solutions and suspensions designed for use in a Respimat®.
  • Formulations ready for use may be produced from the concentrates, for example, by the addition of isotonic saline solutions.
  • Sterile formulations ready for use may be administered using energy-operated free-standing or portable nebulisers which produce inhalable aerosols by means of ultrasound or compressed air by the Venturi principle or other principles.
  • the present invention relates to pharmaceutical compositions in the form of propellant-free inhalable solutions or suspensions as described hereinbefore which take the form of concentrates or sterile formulations ready for use, combined with a device suitable for administering these solutions, characterised in that the device is an energy-operated free-standing or portable nebuliser which produces inhalable aerosols by means of ultrasound or compressed air by the Venturi principle or other methods.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (23)

  1. Pharmazeutische Zusammensetzungen, dadurch gekennzeichnet, dass sie ein Salz oder mehrere Salze der Formel 1
    Figure imgb0005
     worin
    X- ein Anion mit einer einzelnen negativen Ladung, vorzugsweise ein Anion, ausgewählt aus der Gruppe, bestehend aus Fluorid, Chlorid, Bromid, Iodid, Sulfat, Phosphat, Methansulfonat, Nitrat, Maleat, Acetat, Citrat, Fumarat, Tartrat, Oxalat, Succinat, Benzoat und p-Toluolsulfonat, bezeichnet, gegebenenfalls in Form der Racemate, Enantiomeren und der Hydrate davon,
    kombiniert mit einem oder mehreren Betamimetika (2), gegebenenfalls in Form der Enantiomeren, von Gemischen der Enantiomeren oder in Form der Racemate davon, gegebenenfalls in Form der Solvate oder Hydrate, und gegebenenfalls zusammen mit einem pharmazeutisch annehmbaren Exzipienten bzw. Hilfsstoff, enthalten.
  2. Pharmazeutische Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, dass die aktiven Substanzen 1 und 2 entweder zusammen in einer einzelnen Formulierung oder in zwei getrennten Formulierungen vorliegen.
  3. Pharmazeutische Zusammensetzung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass die Betamimetika 2 ausgewählt sind aus der Gruppe, bestehend aus Albuterol, Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Fenoterol, Formoterol, Hexoprenalin, Ibuterol, Isoetharin, Isoprenalin, Levosalbutamol, Mabuterol, Meluadrin, Metaproterenol, Orciprenalin, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrin, Salmeterol, Salmefamol, Soterenot, Sulfonterol, Tiaramid, Terbutalin, Tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3-(4-{6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzolsulfonamid, 5-[2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-chinolin-2-on, 4-Hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)-propyl]-sulfonyl}-ethyl]-amino}-ethyl]-2(3H)-benzothiazolon, 1-(2-Fluor-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol, 1-[3-(4-Methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butyl-amino}-ethanol, 5-Hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-on, 1-(4-Amino-3-chlor-5-trifluormethylphenyl)-2-tert-butylamino)-ethanol und 1-(4-Ethoxycarbonylamino-3-cyano-5-fluorphenyl)-2-(tert-butylamino)-ethanol, gegebenenfalls in Form der Racemate, der Enantiomeren, der Diastereomeren und gegebenenfalls der pharmakologisch annehmbaren Säureadditionssalze und der Hydrate davon.
  4. Pharmazeutische Zusammensetzungen nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass die Verbindungen 2 in Form der Salze von Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Methansulfonsäure, Essigsäure, Fumarsäure, Bernsteinsäure, Milchsäure, Zitronensäure, Weinsäure, 1-Hydroxy-2-naphthalincarbonsäure, 4-Phenylzimtsäure, 5-(2,4-Difluorphenyl)-salicylsäure oder Maleinsäure oder Gemischen davon vorliegen.
  5. Pharmazeutische Zusammensetzungen nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass die Verbindungen 2 ausgewählt sind aus der Gruppe, bestehend aus Bambuterol, Bitolterol, Carbuterol, Clenbuterol, Fenoterol, Formoterol, Hexoprenalin, Ibuterol, Pirbuterol, Procaterol, Reproterol, Salmeterol, Sulfonterol, Terbutalin, Tolubuterol, 3-(4-{6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzolsulfonamid, 5-[2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-chinolin-2-on, 4-Hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)-propyl]-sulfonyl}-ethyl]-amino}-ethyl]-2(3H)-benzothiazolon, 1-(2-Fluor-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol, 1-[3-(4-Methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino}-ethanol, 5-Hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-on, 1-(4-Amino-3-chlor-5-trifluormethylphenyl)-2-tert-butylamino)-ethanol und 1-(4-Ethoxy-carbonylamino-3-cyano-5-fluorphenyl)-2-(tert-butylamino)-ethanol, gegebenenfalls in Form der Racemate, der Enantiomeren, der Diastereomeren und gegebenenfalls der pharmakologisch annehmbaren Säureadditionssalze und der Hydrate davon.
  6. Pharmazeutische Zusammensetzungen nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass die Verbindungen 2 ausgewählt sind aus Fenoterol, Formoterol, Salmeterol, 3-(4-{6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzolsulfonamid, 5-[2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-chinolin-2-on, 1-[3-(4-Methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]-ethanol, 1-[2H-5-Hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino}-ethanol, gegebenenfalls in Form der Racemate, der Enantiomeren, der Diastereomeren und gegebenenfalls der pharmakologisch annehmbaren Säureadditionssalze davon und der Hydrate davon.
  7. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass die Verbindungen der Formel 1 in Form der Enantiomeren der Formel 1-en vorliegen
    Figure imgb0006
  8. Pharmazeutische Zusammensetzungen nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, dass die Gewichtsverhältnisse von 1 zu 2' im Bereich von etwa 1:5 bis 500:1, vorzugsweise 1:10 bis 400:1 liegen.
  9. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, dass sie in Form einer Präparation ist, die zur Inhalation geeignet ist.
  10. Pharmazeutische Zusammensetzung nach Anspruch 9, dadurch gekennzeichnet, dass sie eine Präparation ist, die ausgewählt ist aus inhalierbaren Pulvern, Treibmittel enthaltenden Dosier-Aerosolen und treibmittelfreien inhalierbaren Lösungen.
  11. Pharmazeutische Zusammensetzung nach Anspruch 10, dadurch gekennzeichnet, dass sie ein inhalierbares Pulver ist, das 1 und 2 im Gemisch mit geeigneten physiologisch annehmbaren Exzipienten bzw. Hilfsstoffen enthält, die unter den Monosacchariden, Disacchariden, Oligo- und Polysacchariden, Polyalkoholen, Salzen oder Gemischen dieser Exzipienten miteinander ausgewählt sind.
  12. Inhalierbares Pulver nach Anspruch 11, dadurch gekennzeichnet, dass das Exzipiens bzw. der Hilfsstoff eine maximale durchschnittliche Partikelgröße von bis zu 250 µm, vorzugsweise zwischen 10 und 150 µm, hat.
  13. Pharmazeutische Zusammensetzung nach Anspruch 12, dadurch gekennzeichnet, dass sie ein inhalierbares Pulver ist, das nur die aktiven Substanzen bzw. Wirkstoffe 1 und 2 als seine Bestandteile enthält.
  14. Pharmazeutische Zusammensetzung nach Anspruch 10, dadurch gekennzeichnet, dass sie ein Treibmittel enthaltendes inhalierbares Aerosol ist, das 1 und 2 in gelöster oder dispergierter Form enthält.
  15. Treibmittel enthaltendes inhalierbares Aerosol nach Anspruch 14, dadurch gekennzeichnet, dass es als Treibmittelgas Kohlenwasserstoffe, zum Beispiel n-Propan, n-Butan oder Isobutan oder Halogenkohlenwasserstoffe, zum Beispiel chlorierte und/oder fluorierte Derivate von Methan, Ethan, Propan, Butan, Cyclopropan oder Cyclobutan enthält.
  16. Treibmittel enthaltendes inhalierbares Aerosol nach Anspruch 15, dadurch gekennzeichnet, dass das Treibmittelgas TG11, TG12, TG134a, TG227 oder Gemische davon, vorzugsweise TG134a, TG227 oder ein Gemisch davon, ist.
  17. Treibmittel enthaltendes inhalierbares Aerosol nach einem der Ansprüche 14 bis 16, dadurch gekennzeichnet, dass es bis zu 5 Gew.-% an aktiver Substanz bzw. Wirkstoff 1 und/oder 2 enthalten kann.
  18. Pharmazeutische Zusammensetzung nach Anspruch 10, dadurch gekennzeichnet, dass sie eine treibmittelfreie inhalierbare Lösung ist, die Wasser, Ethanol oder ein Gemisch aus Wasser und Ethanol als Lösungsmittel enthält.
  19. Inhalierbare Lösung nach Anspruch 18, dadurch gekennzeichnet, dass sie gegebenenfalls andere Co-Lösungsmittel und/oder Exzipienten bzw. Hilfsstoffe enthält.
  20. Inhalierbare Lösung nach Anspruch 19, dadurch gekennzeichnet, dass sie als Co-Lösungsmittel Bestandteile enthält, welche Hydroxylgruppen oder andere polare Gruppen enthalten, zum Beispiel Alkohole - insbesondere Isopropylalkohol, Glykole - insbesondere Propylenglykol, Polyethylenglykol, Polypropylenglykol, Glykolether, Glycerin, Polyoxyethylenalkohole und Polyoxyethylenfettsäureester.
  21. Inhalierbare Lösungen nach einem der Ansprüche 19 oder 20, dadurch gekennzeichnet, dass sie als Exzipienten bzw. Hilfsstoffe oberflächenaktive Mittel, Stabilisatoren, Komplexierungsmittel, Antioxidanzien und/oder Konservierungsmittel, Aromen, pharmakologisch annehmbare Salze und/oder Vitamine enthalten.
  22. Inhalierbare Lösungen nach Anspruch 21, dadurch gekennzeichnet, dass sie als Komplexierungsmittel Edetinsäure oder ein Salz von Edetinsäure, vorzugsweise Natriumedetat, enthalten.
  23. Verwendung einer Zusammensetzung nach einem der Ansprüche 1 bis 22 zur Herstellung eines Medikaments für die Behandlung einer Entzündung oder obstruktiver respiratorischer Erkrankungen, insbesondere Asthma oder COPD.
EP04741130A 2003-07-29 2004-07-17 Medikamente zur inhalation mit betamimetika und einem anticholinergikum Revoked EP1651270B1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SI200430315T SI1651270T1 (sl) 2003-07-29 2004-07-17 Zdravila za inhalacijo, ki obsegajo betamimetike in antiholinergik
EP06122278A EP1803469A3 (de) 2003-07-29 2004-07-17 Arzneimittel zur inhalation, enthaltend ein anticholinergicum und ein beta-mimeticum
PL04741130T PL1651270T3 (pl) 2003-07-29 2004-07-17 Leki do inhalacji zawierające betamimetyki i środki przeciwcholinergiczne
EP04741130A EP1651270B1 (de) 2003-07-29 2004-07-17 Medikamente zur inhalation mit betamimetika und einem anticholinergikum
CY20071100456T CY1106430T1 (el) 2003-07-29 2007-04-02 Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03017163 2003-07-29
PCT/EP2004/008030 WO2005014044A1 (en) 2003-07-29 2004-07-17 Medicaments for inhalation comprising betamimetics and an anticholinergic
EP04741130A EP1651270B1 (de) 2003-07-29 2004-07-17 Medikamente zur inhalation mit betamimetika und einem anticholinergikum

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06122278A Division EP1803469A3 (de) 2003-07-29 2004-07-17 Arzneimittel zur inhalation, enthaltend ein anticholinergicum und ein beta-mimeticum

Publications (2)

Publication Number Publication Date
EP1651270A1 EP1651270A1 (de) 2006-05-03
EP1651270B1 true EP1651270B1 (de) 2007-03-21

Family

ID=34130039

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06122278A Withdrawn EP1803469A3 (de) 2003-07-29 2004-07-17 Arzneimittel zur inhalation, enthaltend ein anticholinergicum und ein beta-mimeticum
EP04741130A Revoked EP1651270B1 (de) 2003-07-29 2004-07-17 Medikamente zur inhalation mit betamimetika und einem anticholinergikum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06122278A Withdrawn EP1803469A3 (de) 2003-07-29 2004-07-17 Arzneimittel zur inhalation, enthaltend ein anticholinergicum und ein beta-mimeticum

Country Status (21)

Country Link
EP (2) EP1803469A3 (de)
JP (1) JP2007500151A (de)
KR (1) KR20060052911A (de)
CN (1) CN1829534A (de)
AT (1) ATE357258T1 (de)
AU (1) AU2004262902B2 (de)
BR (1) BRPI0413129A (de)
CA (1) CA2534132C (de)
CY (1) CY1106430T1 (de)
DE (1) DE602004005462T2 (de)
DK (1) DK1651270T3 (de)
ES (1) ES2284025T3 (de)
IL (1) IL173371A0 (de)
MX (1) MXPA06001047A (de)
NZ (1) NZ545442A (de)
PL (1) PL1651270T3 (de)
PT (1) PT1651270E (de)
RU (1) RU2375059C2 (de)
SI (1) SI1651270T1 (de)
WO (1) WO2005014044A1 (de)
ZA (1) ZA200600372B (de)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20070179181A1 (en) * 2004-03-17 2007-08-02 Baxter Andrew D Treatment of inflammatory disorders and pain using beta-aminoalcohols
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
ES2257152B1 (es) † 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
MX2008001976A (es) 2005-08-15 2008-03-25 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos.
JP2010519195A (ja) 2007-02-19 2010-06-03 シプラ・リミテッド 薬学的組成物
EP2666465A1 (de) * 2012-05-25 2013-11-27 Almirall, S.A. Neuartige Dosierung und Formulierung
RU2510267C2 (ru) * 2012-06-15 2014-03-27 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
CZ2014188A3 (cs) 2014-03-26 2015-10-07 Zentiva, K.S. Nové formy aclidinium chloridu a způsob jejich přípravy
PT108370B (pt) 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004118A2 (en) * 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IL107120A (en) 1992-09-29 1997-09-30 Boehringer Ingelheim Int Atomising nozzle and filter and spray generating device
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19536903C2 (de) 1995-10-04 1998-09-10 Boehringer Ingelheim Int Vorrichtung zum Haltern eines fluidischen Bauteils
DE19545226C1 (de) 1995-12-05 1997-06-19 Boehringer Ingelheim Int Sperrspannwerk für einen federbetätigten Abtrieb
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
MXPA04002401A (es) * 2001-09-14 2004-05-31 Boehringer Ingelheim Pharma Nuevos medicamentos para inhalacion.
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
DE10216333A1 (de) * 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004118A2 (en) * 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
US8703806B2 (en) 2009-05-29 2014-04-22 Pearl Therapeutics, Inc. Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials

Also Published As

Publication number Publication date
DE602004005462D1 (de) 2007-05-03
MXPA06001047A (es) 2006-04-24
IL173371A0 (en) 2006-06-11
BRPI0413129A (pt) 2006-10-03
NZ545442A (en) 2010-05-28
EP1803469A2 (de) 2007-07-04
AU2004262902A1 (en) 2005-02-17
WO2005014044A1 (en) 2005-02-17
PT1651270E (pt) 2007-04-30
SI1651270T1 (sl) 2007-08-31
KR20060052911A (ko) 2006-05-19
JP2007500151A (ja) 2007-01-11
EP1651270A1 (de) 2006-05-03
AU2004262902B2 (en) 2009-07-30
CN1829534A (zh) 2006-09-06
PL1651270T3 (pl) 2007-06-29
DE602004005462T2 (de) 2007-07-05
RU2006105713A (ru) 2007-09-10
ZA200600372B (en) 2006-12-27
EP1803469A3 (de) 2011-10-26
CA2534132A1 (en) 2005-02-17
ATE357258T1 (de) 2007-04-15
RU2375059C2 (ru) 2009-12-10
ES2284025T3 (es) 2007-11-01
DK1651270T3 (da) 2007-07-16
CY1106430T1 (el) 2011-10-12
CA2534132C (en) 2013-11-26

Similar Documents

Publication Publication Date Title
US7244742B2 (en) Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
CA2455167C (en) New pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20060057074A1 (en) Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20100330186A1 (en) Medicaments for inhalation comprising an anticholinergic and a betamimetic
CA2495454C (en) Pharmaceutical compositions for inhalation containing a new anticholinergic in conjunction with corticosteroids and betamimetics
ZA200600372B (en) Medicaments for inhalation comprising betamimetics and an anticholinergic
US20020189610A1 (en) Pharmaceutical compositions containing an ipratropium salt and a betamimetic
EP1651224B1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
US20020179087A1 (en) Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US20060079544A1 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
US20060034776A1 (en) Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics
EP1843764B1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
US20060239908A1 (en) Compositions for inhalation
CA2533791C (en) Medicaments for inhalation comprising betamimetics and an anticholinergic agent
US20050107417A1 (en) Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
US20070021333A1 (en) Pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins
CA2553369A1 (en) Pharmaceutical compositions based on anticholinergics and pegsunercept

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20060524BHEP

Ipc: A61K 45/06 20060101AFI20060524BHEP

Ipc: A61K 31/46 20060101ALI20060524BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070400992

Country of ref document: GR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070326

REF Corresponds to:

Ref document number: 602004005462

Country of ref document: DE

Date of ref document: 20070503

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E001033

Country of ref document: EE

Effective date: 20070323

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E001701

Country of ref document: HU

ET Fr: translation filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: 7276

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2284025

Country of ref document: ES

Kind code of ref document: T3

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: LABORATORIOS ALMIRALL S.A.

Effective date: 20071221

NLR1 Nl: opposition has been filed with the epo

Opponent name: LABORATORIOS ALMIRALL S.A.

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: GB

Ref legal event code: S75

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080722

Year of fee payment: 5

REG Reference to a national code

Ref country code: GB

Ref legal event code: S75Z

Free format text: PATENT REVOKED.

Ref country code: GB

Ref legal event code: S75Z

Free format text: APPLICATION TO AMEND UNDER SECTION 75 FILED ON 18 AUGUST 2008 REFUSED AND PATENT REVOKED BY COURT ORDER DATED 27 FEBRUARY 2009. TERMS OF ORDER DATED 27 FEBRUARY 2009 STAYED, PENDING APPEAL (HC 07 C02104).

Ref country code: GB

Ref legal event code: S72

Free format text: PATENT REVOKED BY COURT ORDER DATED 27 FEBRUARY 2009 (HC07 C02104)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20090227

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20100812

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100714

Year of fee payment: 7

Ref country code: DE

Payment date: 20100723

Year of fee payment: 7

Ref country code: EE

Payment date: 20100720

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20100709

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R103

Ref document number: 602004005462

Country of ref document: DE

Ref country code: DE

Ref legal event code: R064

Ref document number: 602004005462

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20110630

Year of fee payment: 8

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20110725

Year of fee payment: 8

27W Patent revoked

Effective date: 20110712

REG Reference to a national code

Ref country code: PT

Ref legal event code: MP4A

Effective date: 20110919

REG Reference to a national code

Ref country code: EE

Ref legal event code: MF4A

Ref document number: E001033

Country of ref document: EE

Effective date: 20110906

REG Reference to a national code

Ref country code: DE

Ref legal event code: R107

Ref document number: 602004005462

Country of ref document: DE

Effective date: 20111027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20070321

Ref country code: LI

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20070321

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110729

Year of fee payment: 8

Ref country code: IE

Payment date: 20110721

Year of fee payment: 8

Ref country code: CH

Payment date: 20110725

Year of fee payment: 8

Ref country code: BG

Payment date: 20110714

Year of fee payment: 8

Ref country code: DK

Payment date: 20110720

Year of fee payment: 8

Ref country code: MC

Payment date: 20110714

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20110713

Year of fee payment: 8

Ref country code: PL

Payment date: 20110624

Year of fee payment: 8

Ref country code: SI

Payment date: 20110628

Year of fee payment: 8

Ref country code: RO

Payment date: 20110629

Year of fee payment: 8

Ref country code: GR

Payment date: 20110727

Year of fee payment: 8

Ref country code: TR

Payment date: 20110704

Year of fee payment: 8

Ref country code: SE

Payment date: 20110722

Year of fee payment: 8

Ref country code: CZ

Payment date: 20110714

Year of fee payment: 8

Ref country code: FI

Payment date: 20110714

Year of fee payment: 8

Ref country code: ES

Payment date: 20110726

Year of fee payment: 8

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20110726

Year of fee payment: 8

Ref country code: BE

Payment date: 20110713

Year of fee payment: 8

Ref country code: IT

Payment date: 20110728

Year of fee payment: 8

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20070400992

Country of ref document: GR

Effective date: 20130104

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20130221

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 1719

Country of ref document: SK

Effective date: 20120717